AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Protagonist Therapeutics, Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG002B63KP4
138.43▼ 0.97 (-0.69%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
139.40
Day's Range
135.00 – 139.52
52-Week Range
73.08 – 160.81
Volume
408.5K
Avg Volume
765.0K
Share Statistics
Shares Outstanding
Employees
132
Exchange
XNAS
Listed
2016-08-11
Share count as of July 31, 2026

Protagonist Therapeutics, Inc (PTGX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Protagonist Therapeutics, Inc (PTGX)
What is Protagonist Therapeutics, Inc's Market Cap?
Protagonist Therapeutics, Inc's Market Cap is $9.0B, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's Enterprise Value?
Protagonist Therapeutics, Inc's Enterprise Value is $8.2B, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's Trailing P/E?
Protagonist Therapeutics, Inc's Trailing P/E is 108.0×, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's Price / Sales?
Protagonist Therapeutics, Inc's Price / Sales is 194.7×, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's EV / Revenue?
Protagonist Therapeutics, Inc's EV / Revenue is 177.7×, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's EV / EBITDA?
Protagonist Therapeutics, Inc's EV / EBITDA is 137.6×, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's Revenue (TTM)?
Protagonist Therapeutics, Inc's Revenue (TTM) is $46.0M, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's Net Income (TTM)?
Protagonist Therapeutics, Inc's Net Income (TTM) is $82.9M, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's EBITDA?
Protagonist Therapeutics, Inc's EBITDA is $59.9M, based on as-reported figures from SEC (XBRL) filings.
What is Protagonist Therapeutics, Inc's Diluted EPS (TTM)?
Protagonist Therapeutics, Inc's Diluted EPS (TTM) is 1.28, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PTGXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Operations
License and collaboration revenue
YoY growth+3749.2%+99.0%-95.6%+0.8%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue25.6%106.5%777.1%1085.2%
Income (loss) from operations
% of revenue74.4%-6.5%-677.1%-985.2%
Interest income
Other (expense) income, net
Income (loss) before income tax expense
Income tax expense
Net income (loss)
% of revenue76.3%6.7%-596.8%-834.9%
Net income (loss) per share, basic (in dollar per share)
Net income (loss) per share, diluted (in dollar per share)